Astellas Pharma
Padcev-Keytruda combo cuts death risk in first-line bladder cancer
As Seagen readies itself for its impending acquisition by Pfizer, a significant triumph emerges for the company’s cancer drug Padcev, ...
Taysha halts gene therapy for rare nerve disease after FDA and Astellas feedback
Astellas has declined the opportunity to exercise an option for an asset from Taysha Gene Therapies. Taysha, facing study design ...
Astellas to invest $354M in new Irish plant for antibody drugs
Astellas is strengthening its significant presence in Ireland with a substantial investment of 330 million euros ($354 million) in a ...
Sandoz Acquires Mycamine, a Top Antifungal Drug, from Astellas
In the ever-evolving landscape of medical advancements, Sandoz emerges as a dominant force, orchestrating a strategic move that echoes across ...
FDA Approves Izervay for Geographic Atrophy
Source – Astellas Pharma Astellas Pharma has received FDA approval for Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic ...
Astellas and Eko Partner for Heart Failure Digital Therapeutics with Eko CORE 500™ Stethoscope
Source – Astellas Pharma Astellas has obtained the licensing rights to a smart stethoscope device developed by Eko Health, with ...
Fezolinetant’s Phase IIIb Trial Demonstrates Promising Topline Results in Treating Menopause-related Vasomotor Symptoms (VMS)
Source – Astellas Pharma Astellas Pharma recently announced positive preliminary findings on June 27, 2023, from the Phase IIIb DAYLIGHT ...
